These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 17486070)
1. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070 [TBL] [Abstract][Full Text] [Related]
2. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782 [TBL] [Abstract][Full Text] [Related]
3. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427 [TBL] [Abstract][Full Text] [Related]
4. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283 [TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Wang S; Wilkes MC; Leof EB; Hirschberg R FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551 [TBL] [Abstract][Full Text] [Related]
9. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Ling X; Ma G; Sun T; Liu J; Arlinghaus RB Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778 [TBL] [Abstract][Full Text] [Related]
10. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488 [TBL] [Abstract][Full Text] [Related]
12. Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin. Jin H; Wang JY Mol Biol Cell; 2007 Oct; 18(10):4143-54. PubMed ID: 17686996 [TBL] [Abstract][Full Text] [Related]
13. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Ito I; Ji L; Tanaka F; Saito Y; Gopalan B; Branch CD; Xu K; Atkinson EN; Bekele BN; Stephens LC; Minna JD; Roth JA; Ramesh R Cancer Gene Ther; 2004 Nov; 11(11):733-9. PubMed ID: 15486560 [TBL] [Abstract][Full Text] [Related]
14. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Liu J; Wu Y; Arlinghaus RB Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843 [TBL] [Abstract][Full Text] [Related]
15. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873 [TBL] [Abstract][Full Text] [Related]
16. Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase. Stephens RS; Servinsky LE; Rentsendorj O; Kolb TM; Pfeifer A; Pearse DB Am J Physiol Cell Physiol; 2014 Mar; 306(6):C559-69. PubMed ID: 24401847 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells. Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407 [TBL] [Abstract][Full Text] [Related]